Difference between revisions of "ELF3-AS1"
Qianpeng Li (talk | contribs) |
|||
| Line 2: | Line 2: | ||
==Annotated Information== | ==Annotated Information== | ||
===Name=== | ===Name=== | ||
| − | ELF3-AS1:ELF3 antisense RNA 1 | + | Approved symbol: ELF3-AS1:ELF3 antisense RNA 1 |
| − | ENST00000415582 <ref name="ref1" /> | + | Approved symbol: ENST00000415582 <ref name="ref1" />, SCAT7 |
| + | |||
| + | HGNC ID: HGNC:40211 | ||
| + | |||
| + | LncBook transcript ID: HSALNT0288941 | ||
===Function=== | ===Function=== | ||
ELF3-AS1 may be used as novel and minimally invasive markers for the diagnosis and prognostic assessment of non-131I-avid lung metastases from Papillary Thyroid Cancer(PTC) <ref name="ref1" />. ELF3-AS1 has high diagnostic sensitivity and specificity for predicting non-131I-avid lung metastases of PTC, and low ELF3-AS1 lncRNA level is associated with better prognosis of PTC patients with lung metastases (P<0.001) <ref name="ref1" />. | ELF3-AS1 may be used as novel and minimally invasive markers for the diagnosis and prognostic assessment of non-131I-avid lung metastases from Papillary Thyroid Cancer(PTC) <ref name="ref1" />. ELF3-AS1 has high diagnostic sensitivity and specificity for predicting non-131I-avid lung metastases of PTC, and low ELF3-AS1 lncRNA level is associated with better prognosis of PTC patients with lung metastases (P<0.001) <ref name="ref1" />. | ||
| + | |||
| + | Depletion of SCAT7 in Caki-2 cells altered cell proliferation, inhibited cell cycle progression, and induced apoptosis. SCAT7 interacts with hnRNPK/YBX1 complex and affects cancer cell hallmarks through the regulation of FGF/FGFR and its downstream PI3K/AKT and MAPK pathways<ref name="ref2" />. | ||
===Expression=== | ===Expression=== | ||
[[File:ENST00000415582.JPG|right|thumb|400px|'''Expression of ELF3-AS1 in Papillary Thyroid Cancer patients''' <ref name="ref1" />.]] | [[File:ENST00000415582.JPG|right|thumb|400px|'''Expression of ELF3-AS1 in Papillary Thyroid Cancer patients''' <ref name="ref1" />.]] | ||
ELF3-AS1 is significantly upregulated in samples from the non-131I-avid lung metastasis group comparing with 131I-avid lung metastasis group(p<0.05) <ref name="ref1" />. | ELF3-AS1 is significantly upregulated in samples from the non-131I-avid lung metastasis group comparing with 131I-avid lung metastasis group(p<0.05) <ref name="ref1" />. | ||
| + | |||
| + | SCAT7 was upregulated in multiple cancers (BLCA, BRCA, KIRP, LIHC, LUAD, LUSC, PRAD, and UCEC). The temporal expression analysis of SCAT7 during cell cycle progression indicated elevated levels in the S-phase of HeLa and Caki-2 cell lines<ref name="ref2" />. | ||
===Diseases=== | ===Diseases=== | ||
Papillary Thyroid Cancer <ref name="ref1" /> | Papillary Thyroid Cancer <ref name="ref1" /> | ||
| + | |||
| + | Multiple cancers including BLCA, BRCA, KIRP, LIHC, LUAD, LUSC, PRAD, and UCEC<ref name="ref2" />. | ||
===Sequence=== | ===Sequence=== | ||
>XR_426886.2 PREDICTED: Homo sapiens uncharacterized LOC102723465 (LOC102723465), ncRNA | >XR_426886.2 PREDICTED: Homo sapiens uncharacterized LOC102723465 (LOC102723465), ncRNA | ||
| Line 23: | Line 33: | ||
==Labs working on this lncRNA== | ==Labs working on this lncRNA== | ||
*Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. | *Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. | ||
| + | *Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 40530, Sweden. | ||
==References== | ==References== | ||
<references> | <references> | ||
| Line 30: | Line 41: | ||
Papillary Thyroid Cancer Patients with Lung Metastases. Cell Physiol Biochem. | Papillary Thyroid Cancer Patients with Lung Metastases. Cell Physiol Biochem. | ||
2016;40(6):1377-1390. | 2016;40(6):1377-1390. | ||
| − | </ref> | + | </ref>(1) |
| + | <ref name="ref2"> | ||
| + | Ali MM, Akhade VS, Kosalai ST, Subhash S, Statello L, Meryet-Figuiere M, Abrahamsson J, Mondal T, Kanduri C. PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers. Nat Commun. 2018 Feb 28;9(1):883. doi: 10.1038/s41467-018-03265-1. | ||
| + | </ref>(2) | ||
</references> | </references> | ||
Latest revision as of 05:15, 7 August 2019
Contents
Annotated Information
Name
Approved symbol: ELF3-AS1:ELF3 antisense RNA 1
Approved symbol: ENST00000415582 [1], SCAT7
HGNC ID: HGNC:40211
LncBook transcript ID: HSALNT0288941
Function
ELF3-AS1 may be used as novel and minimally invasive markers for the diagnosis and prognostic assessment of non-131I-avid lung metastases from Papillary Thyroid Cancer(PTC) [1]. ELF3-AS1 has high diagnostic sensitivity and specificity for predicting non-131I-avid lung metastases of PTC, and low ELF3-AS1 lncRNA level is associated with better prognosis of PTC patients with lung metastases (P<0.001) [1].
Depletion of SCAT7 in Caki-2 cells altered cell proliferation, inhibited cell cycle progression, and induced apoptosis. SCAT7 interacts with hnRNPK/YBX1 complex and affects cancer cell hallmarks through the regulation of FGF/FGFR and its downstream PI3K/AKT and MAPK pathways[2].
Expression
ELF3-AS1 is significantly upregulated in samples from the non-131I-avid lung metastasis group comparing with 131I-avid lung metastasis group(p<0.05) [1].
SCAT7 was upregulated in multiple cancers (BLCA, BRCA, KIRP, LIHC, LUAD, LUSC, PRAD, and UCEC). The temporal expression analysis of SCAT7 during cell cycle progression indicated elevated levels in the S-phase of HeLa and Caki-2 cell lines[2].
Diseases
Papillary Thyroid Cancer [1]
Multiple cancers including BLCA, BRCA, KIRP, LIHC, LUAD, LUSC, PRAD, and UCEC[2].
Sequence
>XR_426886.2 PREDICTED: Homo sapiens uncharacterized LOC102723465 (LOC102723465), ncRNA
000081 CCAGCGCCCA CTCTGTTGGC AAGGTCTTCA CTACCATCAC CTGCCTGGAC TCCATCCAAG CATCAGGGTT GCTGCAGTCG 000160
000161 CTCCTGAAGA GACCCGGCTC TGCTTGAAAG TTCTTCCCTC AGCGCCTGCT GGAGCCCTCC CTGCCGGAGT TGCCAGAATC 000240
000241 CACACGGAAT CCACAGATCT GCCCTGATGA TCATGAAGGA ATGCGAAAGA GCCTGGTAAA ACGATATGGA CTTGTGCAAA 000320
000321 TGCAAAGCAA TGGTGAAGTC ATCACGAACC GCACAGACTG GACAGAACTC CTATCTGGCT GCAATGGCTT GGGTTCAGTC 000400
000401 AGCCCAGGGG CCAGAGAATT GGCTACAAAG AGCTCTGGAG TGCCCCTCCC TCCAAATAAA GTATTCTAAG CGTGCACTGA 000480
Labs working on this lncRNA
- Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
- Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 40530, Sweden.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Qiu ZL, Shen CT, Sun ZK, Wei WJ, Zhang XY, Song HJ, Luo QY. Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases. Cell Physiol Biochem. 2016;40(6):1377-1390.
- ↑ 2.0 2.1 2.2 Ali MM, Akhade VS, Kosalai ST, Subhash S, Statello L, Meryet-Figuiere M, Abrahamsson J, Mondal T, Kanduri C. PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers. Nat Commun. 2018 Feb 28;9(1):883. doi: 10.1038/s41467-018-03265-1.
